Abstract: A non-transitory computer readable medium stores a program causing a computer to execute: allowing a player to select a character to be used in each of a plurality of category games included in a specific game; setting the character selected by the player for each category game; deriving an individual game result for each category game; determining, for each category game, a predetermined parameter associated with the character used in the category game; ranking a plurality of characters based on the predetermined parameters of the plurality of category games, the plurality of characters being used in the specific game in accordance with the selection by the player; and deriving an overall game result based on the individual game result of each of the plurality of category games or the predetermined parameters of the plurality of category games.

Abstract: An antifouling coating composition contains a silyl ester (co)polymer and medetomidine and is used to prevent the fouling of substrates by aquatic organisms and which can form antifouling coating films exhibiting outstanding antifouling properties over a long period and also has good storage stability. The antifouling coating composition includes a silyl ester (co)polymer (A) and medetomidine (B), the silyl ester (co)polymer (A) including structural units derived from a monomer (a) represented by the general formula (I): R1—CH?C(CH3)—COO—(SiR2R3O)n—SiR4R5R6, and structural units derived from an unsaturated monomer (b) copolymerizable with the monomer (a).

Abstract: An antifouling coating composition contains a silyl ester (co)polymer and medetomidine and is used to prevent the fouling of substrates by aquatic organisms and which can form antifouling coating films exhibiting outstanding antifouling properties over a long period and also has good storage stability. The antifouling coating composition includes a silyl ester (co)polymer (A) and medetomidine (B), the silyl ester (co)polymer (A) including structural units derived from a monomer (a) represented by the general formula (I): R1—CH?C(CH3)—COO—(SiR2R3O)n—SiR4R5R6, and structural units derived from an unsaturated monomer (b) copolymerizable with the monomer (a).

Abstract: A compound, which inhibits SGLT1 (sodium-dependent glucose transporter 1) activity to suppress absorption of glucose or the like, thereby suppressing abnormal glucose tolerance or postprandial hyperglycemia in diabetes, is provided.

Abstract: The step-up DC/DC converter (30) of the present invention has a synchronous rectifier transistor (M1); an output transistor (M2); a first back-gate control transistor (M3) connected between an external terminal (T2) and a back gate of the synchronous rectifier transistor (M1); a discharge transistor (M6) connected between the external terminal (T2) and a ground terminal; and a control unit (X1) for controlling the on/off state of the components described above. The control unit (X1) switches off the first back-gate control transistor (M3) and switches on the discharge transistor (M6) when stopping the switching operation of the output transistor (M2) and the synchronous rectifier transistor (M1).

Abstract: A compound, which inhibits SGLT1 (sodium-dependent glucose transporter 1) activity to suppress absorption of glucose or the like, thereby suppressing abnormal glucose tolerance or postprandial hyperglycemia in diabetes, is provided.

Abstract: The present invention provides 4-isopropylphenyl glucitol compounds which have no tendency to accumulate in the body and which inhibit SGLT1 activity to suppress postprandial hyperglycemia (or impaired glucose tolerance) through suppression of glucose absorption in the small intestine, whereby the compounds, for example, can suppress the onset of diabetes and metabolic syndrome or can treat these diseases. A 4-isopropylphenyl glucitol compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein R1 represents a hydrogen atom, etc., R2 represents a methyl group, etc., R3 represents a C1-4 alkyl group substituted with an amino group(s), etc., and R4 represents a hydrogen atom, etc.

Abstract: The present invention provides 4-isopropylphenyl glucitol compounds which have no tendency to accumulate in the body and which inhibit SGLT1 activity to suppress postprandial hyperglycemia (or impaired glucose tolerance) through suppression of glucose absorption in the small intestine, whereby the compounds, for example, can suppress the onset of diabetes and metabolic syndrome or can treat these diseases. A 4-isopropylphenyl glucitol compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein R1 represents a hydrogen atom, etc., R2 represents a methyl group, etc., R3 represents a C1-4 alkyl group substituted with an amino group(s), etc., and R4 represents a hydrogen atom, etc.

Abstract: Provided is a novel C-phenyl glycitol compound that may serve as a prophylactic or therapeutic agent for diabetes by inhibiting both SGLT1 activity and SGLT2 activity, thereby exhibiting a glucose absorption suppression action and a urine glucose excretion action.

Abstract: The step-up DC/DC converter (30) of the present invention has a synchronous rectifier transistor (M1); an output transistor (M2); a first back-gate control transistor (M3) connected between an external terminal (T2) and a back gate of the synchronous rectifier transistor (M1); a discharge transistor (M6) connected between the external terminal (T2) and a ground terminal; and a control unit (X1) for controlling the on/off state of the components described above. The control unit (X1) switches off the first back-gate control transistor (M3) and switches on the discharge transistor (M6) when stopping the switching operation of the output transistor (M2) and the synchronous rectifier transistor (M1).

Abstract: A 1-phenyl 1-thio-D-glucitol compound represented by formula (I) or the like: or a pharmaceutically acceptable salt thereof or a hydrate thereof, or a pharmaceutical preparation comprising the same as an active ingredient is useful as a novel type of prophylactic or therapeutic agent for diabetes, diabetes-related diseases or diabetic complications, which inhibits both SGLT1 and SGLT2 activities to achieve not only suppression of glucose absorption from the digestive tract but also excretion of urinary sugars.

Abstract: Provided is a novel C-phenyl glycitol compound that may serve as a prophylactic or therapeutic agent for diabetes by inhibiting both SGLT1 activity and SGLT2 activity, thereby exhibiting a glucose absorption suppression action and a urine glucose excretion action.

Abstract: A first transistor is provided between one terminal of a synchronous rectifying transistor and the back gate thereof, with a body diode of the first transistor being in an orientation such that the cathode thereof corresponds to the output terminal side. A second transistor is provided between the other terminal of the synchronous rectifying transistor and the back gate thereof, with a body diode of the second transistor being in an orientation such that the cathode thereof corresponds to the switching terminal side. During a first period from the boosting stopped state up to the boosting operation state of the switching regulator, a switch control unit instructs the synchronous rectifying transistor to perform a switching operation with the switching transistor set to the OFF state, the first transistor set to the ON state, and the second transistor set to the OFF state.

Abstract: A semiconductor device is provided whereby the signal interference among a plurality of function blocks is reduced. In a semiconductor device having a CSP structure, an integrated circuit containing a plurality of function blocks is formed on a semiconductor substrate. A plurality of external electrodes are classified into a plurality of groups of external electrodes according to function blocks connected, and are arranged in a plurality of divided regions for each of the plurality of groups of external electrodes. Rewirings connected to external electrodes of low impedance are placed in a boundary area between the plurality of regions.

Abstract: The present invention is to provide a method for producing an animal natural intestine having improved texture and hardness by treatment with a solution containing a food emulsifier.

Abstract: The present invention is to provide a method for producing an animal natural intestine having improved texture and hardness by treatment with a solution containing a food emulsifier.